SALVAGE SURGERY FOR ANAL CANAL CA. LONG TERM OUTCOMES FROM A TERTIARY REFERRAL CENTRE
Purpose: The purpose of this study was to analyse the outcome of salvage surgery in the management of anal canal cancer.
Methodology: All patients with a diagnosis of anal canal carcinoma from 2006 to 2015 were studied. Basic demographic data were recorded. Treatment modalities used were recorded for all patients. Long-term surgical outcomes were recorded. Median survival in months was recorded. All data were recorded in the SPSS ver. 20.
Results: A total of 62 patients were included in the study. Median age was 51. 38 patients had SCCa on histology and 24 had an adenocarcinoma. 52% of patients had a T4 lesion. Chemoradiotherapy (CRT) was offered to 59 (95%) patients as the first line of therapy. 12 (19%) patients had a complete response. 37 (60%) patients had a partial and 10 (16%) patients had no response to chemoradiation. Salvage surgery was offered to 27 patients. Of these, 21 had a curative resection. Six had irresectable disease and underwent a colostomy only. Median overall survival for all patients was 46 months with a 5-year survival of 55%. Patients with partial response who were offered salvage surgery the 5-year survival were 40%. For patients with no response or progressive disease after chemoradiation therapy, the 5-year survival was 20%.
Conclusion: Long-term survival can be achieved in majority of patients who undergo radical salvage surgery after failed CRT for carcinoma of the anal canal.
Key words: Adenocarcinoma, anal canal, chemoradiotherapy, surgery
Moore HG, Guillem JG. Anal neoplasms. Surg Clin North Am 2002;82:1233-51.
Talbot RW. Changing nature of anal cancer. BMJ 1988;297:239-40.
Golden GT, Horsley JS 3rd. Surgical management of epidermoid carcinoma of the anus. Am J Surg 1976;131:275-80.
Fuchshuber PR, Rodriguez-Bigas M, Weber T, et al. Anal canal and perianal epidermoid cancers. J Am Coll Surg 1997;185:494-505.
Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 1974;17:354-6.
Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR anal cancer trial working party. UK co-ordinating committee on cancer research. Lancet 1996;348:1049-54.
Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997;15:2040-9.
Tanum G, Tveit K, Karlsen KO, et al. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991;67:2462-6.
Akbari RP, Paty PB, Guillem JG, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum 2004;47:1136-44.
Ferenschild FT, Vermaas M, Hofer SO, et al. Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg
Nilsson PJ, Svensson C, Goldman S, et al. Salvage
abdominoperineal resection in anal epidermoid cancer. Br
J Surg 2002;89:1425-9.
Pocard M, Tiret E, Nugent K, et al. Results of salvage abdominoperineal resection for anal cancer after radiotherapy. Dis Colon Rectum 1998;41:1488-93.
van der Wal BC, Cleffken BI, Gulec B, et al. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg 2001;5:383-7.
Renehan AG, Saunders MP, Schofield PF, et al. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 2005;92:605-14.
Papaconstantinou HT, Bullard KM, Rothenberger DA,et al. Salvage abdominoperineal resection after failed nigro protocol: Modest success, major morbidity. Colorectal Dis 2006;8:124-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.